Skip to main content
SpringerLink
Log in

Azetirelin

YM 14673

  • Section 2: Dementia Syndrome in Japan
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Imasaki H, Nakamura E, Yokoi K, et al. Metabolic fate of azetirelin. (2) Disposition and metabolism of azetirelin after intravenous administration to rats. Pharmacometrics 1991 Mar; 41: 213–26

    CAS  Google Scholar 

  2. Sasaki I, Tanaka K, Fujita T, et al. Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. 2. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull 1995 Jul; 18: 976–9

    Article  PubMed  CAS  Google Scholar 

  3. Yamamoto M, Ozawa Y, Takeuchi H. Effects of YM-14673, a new thyrotropin-releasing hormone analogue, on impaired learning of passive avoidance in mice. Arch Int Pharmacodyn Ther 1993 Jan–Feb; 321: 5–13

    PubMed  CAS  Google Scholar 

  4. Yamamoto M, Ozawa Y, Sasamata M, et al. Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents. Eur J Pharmacol 1990 May; 180: 319–24

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azetirelin. Drugs R&D 2, 133–134 (1999). https://doi.org/10.2165/00126839-199902020-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902020-00013

Keywords

Search

Navigation